1	Im	pact of low relative skeletal muscle mass and power on the					
2	dev	elopment of metabolic syndrome in Japanese women: a 7-year					
3	prospective study						
4							
5	Yo	osuke Yamada ^{1*} , Haruka Murakami ^{1,2} , Ryoko Kawakami ^{1,3} , Yuko Gando ^{1,4} , Hinako					
6	Nanri ¹ , Takashi Nakagata ¹ , Daiki Watanabe ¹ , Tsukasa Yoshida ¹ , Yoichi Hatamoto ¹ ,						
7	Eiichi Yoshimura ¹ , Kiyoshi Sanada ² , Nobuyuki Miyatake ⁵ , Motohiko Miyachi ^{1,3}						
8							
9	1	National Institute of Health and Nutrition, National Institutes of Biomedical					
10		Innovation, Health and Nutrition, Tokyo 162-8636, Japan;					
11		yamaday@nibiohn.go.jp, hnanri@nibiohn.go.jp, takashi.nakagata@gmail.com,					
12		d2watanabe@nibiohn.go.jp, t-yoshida@nibiohn.go.jp, yhatamoto@nibiohn.go.jp,					
13		eyoshi@nibiohn.go.jp					
14	2	Faculty of Sport and Health Science, Ritsumeikan University, Kusatsu, Shiga 525-					
15		8577, Japan; haruka-m@fc.ritsumei.ac.jp, ksanada@fc.ritsumei.ac.jp					
16	3	Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama 359-1192,					
17		Japan; r.kawakami@aoni.waseda.jp, miyachim@waseda.jp					
18	4	Faculty of Sport Science, Surugadai University, Hanno, Saitama, 357-8555, Japan;					
19		gando.yuko@surugadai.ac.jp					
20	5	Department of Hygiene, Faculty of Medicine, Kagawa University, Miki, Kagawa,					
21		761-0793, Japan; miyatake.nobuyuki@kagawa-u.ac.jp					
22							
^ 2							

23 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 * Correspondence: Yosuke Yamada, PhD
- 25 National Institute of Health and Nutrition, National Institutes of Biomedical
- 26 Innovation, Health and Nutrition, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8636,
- 27 Japan; yamaday@nibiohn.go.jp

28

30 Abstract: Previous cross-sectional studies indicated that low relative skeletal muscle 31 mass against body weight (appendicular lean mass divided by body weight, ALM/Wt or 32 divided by body mass index, ALM/BMI) was negatively associated with metabolic 33 syndrome (MetS). The aim of this longitudinal study was to investigate the impact of 34 low relative skeletal muscle mass and leg muscle power on the development of MetS in 35 Japanese women in a 7-y prospective study. Subjects were 346 Japanese women aged 36 26 to 85 years. The reference values for Class I sarcopenia were defined as values one 37 SD below the sex-specific means of the young group. The longitudinal relation between 38 muscle mass or leg power and development of MetS was examined using Kaplan-Meier 39 curves and Cox regression models (average follow-up duration 7 years, range 1 to 10 40 years). During follow-up, 24 of subjects developed MetS. Both indices of ALM/Wt or 41 ALM/BMI, the incidence of MetS was higher in Class I sarcopenia group than normal 42 muscle mass group even after controlling variables (adjusted hazard ratio [AHR] = 3.22[95%CI; 1.25-8.27] for ALM/Wt and 3.19 [95%CI; 1.31-7.74] for ALM/BMI). In 43 44 contrast, for the leg power per body weight, the incidence of MetS was not significantly 45 different between low leg power and normal leg power groups (AHR = 1.23 [95%CI; 46 0.50-3.04]). Current longitudinal study indicated that low relative skeletal muscle mass 47 but not low leg power was independent risk factors for the development of MetS in 48 Japanese women.

49

50 Keywords: relative skeletal muscle mass, sarcopenia, muscle power, metabolic
51 syndrome, longitudinal study

53 **1. Introduction**

54 Skeletal muscle mass (SMM) and its function are considered important biomarkers 55 of aging [1-3]. Age-related loss of SMM and its function is called as sarcopenia [4]. In 56 current measureable definition of sarcopenia is based on SMM and grip strength and/or 57 lower body physical performance [1, 2]. Skeletal muscle is a metabolically active organ 58 to mediate energy metabolism and exert beneficial effects on metabolic health [5, 6]. 59 Thus, higher muscle mass or muscle function might have beneficial effect on preventing 60 metabolic syndrome (MetS) as well [7-11]. MetS is a cluster of conditions that occur 61 together, increasing the risk of heart disease, stroke and type 2 diabetes. These conditions 62 include the accumulation of visceral fat, increased blood pressure, dyslipidemia, and 63 hyperglycemia.

64 However, because the people who have higher body weight tend have higher muscle 65 mass and strength, previous studies indicated that the normalization of muscle mass and strength by body weight or body mass index (BMI) is needed to see the association 66 between skeletal muscle mass or strength and MetS [7-14]. Previous cross-sectional 67 68 studies indicated that relative appendicular lean mass per kg weight or per body mass 69 index is inversely associated with MetS [7-14]. The present longitudinal study aimed to 70 examine the impact of low relative skeletal muscle mass and power on the development 71 of MetS in Japanese women.

73 2. Materials and Methods

- 74 *2.1. Ethics approval and consent to participate*
- The study was performed in accordance with the guidelines of the Declaration of
 Helsinki. All procedures were reviewed and approved by the ethics committees of the
 National Institutes of Biomedical Innovation, Health and Nutrition (6008, Kenei14-02).
- 78 All participants provided written consent for participation in the study.

79

80 2.2. Participants

The participants were recruited from the community around the National Institute of Health and Nutrition, Tokyo, Japan. From a total of 760 women, 346 women aged 26 to 85 years old (mean and SD of age, \pm years) were included in the current study who met the following criteria: (1) they received anthropometric and physical activity measurements, (2) underwent blood examinations, (3) dietary intake assessments, (4) no history of MetS at the baseline measurement, and (5) underwent follow-up examinations.

87

88 2.3. Anthropometric and leg power measures

Height, weight, and waist circumference were measured and body mass index
was calculated. Body composition was determined by bioelectrical impedance analysis
(TANITA BC-600). The appendicular lean mass (ALM; kg) were obtained from the
sum of the four limbs (right and left upper and lower limbs). The skeletal muscle index

93	(SMI) was calculated as ALM divided by body weight \times 100 (%). The reference values
94	for Class I sarcopenia were defined as values one SD below the sex-specific means of
95	the young group, and 28.0% was the cutoff value for Class I sarcopenia. In addition,
96	ALM divided by BMI (ALM/BMI) was also calculated based on FNIH
97	recommendation. The cutoff value for Class I sarcopenia of ALM/BMI was 0.670. We
98	used these values to divide the subject into normal muscle mass group and Class I
99	sarcopenia group. No women fell into Class II sarcopenia in the current subjects.
100	The leg extension power was measured by using a dynamometer (Anaero Press
101	3500; Combi Wellness, Tokyo, Japan) in the sitting position [15]. The subjects were
102	advised to vigorously extend their legs. 5 trials were performed at 15-s intervals, and the
103	average of the 2 highest recorded power outputs (watt; W) was taken as the definitive
104	measurement. The leg extension power divided by body weight was obtained.

105

106 2.4. Physical Activity

107 The duration and intensity of physical activity were evaluated by a triaxial 108 accelerometer (Actimarker EW4800; Panasonic, Osaka, Japan) [16, 17], as described 109 previously [15]. Participants were asked to wear the physical activity monitor on their hip 100 for 28 days; we used data for 14 days, during which the accelerometer was worn 111 continuously from the time the participant awoke until she went to bed. Total volume of 112 physical activity (METs \times hour) was obtained.

113

114 2.5. Blood samples

Blood samples were taken from participants following an overnight fast of at least 10 hours [18]. Venous blood withdrawn from the antecubital vein was collected into tubes without additives or EDTA and was immediately centrifuged at 3000 rpm for 20 minutes to obtain serum or plasma. The levels of glucose, HbA1c, homeostasis model assessment of insulin resistance (HOMA-IR), and HOMA- β in plasma and total cholesterol, highdensity and low-density lipoprotein (HDL and LDL) cholesterol, and triglycerides in serum were determined [15].

122 According to the definition released by the Japanese Committee for the Diagnostic 123 Criteria of Metabolic Syndrome in April 2005, we defined metabolic syndrome as the 124 presence of 2 or more abnormalities in addition to visceral obesity (waist circumference: 125 85 cm or more in men, 90 cm or more in women). These three abnormalities are as 126 follows: 1, triglycerides ≥150 mg/dL and/or HDL-cholesterol <40 mg/dL or under 127 treatment for this type of dyslipidemia, 2, systolic blood pressure \geq 130 and/or diastolic 128 blood pressure \geq 85, or under treatment for hypertension, 3, fasting glucose \geq 110 mg/dL 129 or under treatment for diabetes [19].

130

131 2.6. Statistical analysis

Results are presented as mean ± standard deviation (SD). Differences were analyzed using ANOVA. Cumulative event rates for incident MetS were estimated by Kaplan-Meier curves, and the equalities were compared with the log-rank test. Cox proportional hazard analysis was performed to determine the independent association between either baseline SMI, ALM/BMI, or leg power against other variables. For

- 137 multivariate analysis, model 1 was a crude form; age was adjusted for in model 2; model
- 138 3 included model-2 adjustment and family history of diabetes, smoking status, and
- 139 physical activity. Alpha of 0.05 was employed to denote significant statistical deviation.
- 140 We performed all analyses using IBM SPSS Statistics for Windows, version 22.0 (IBM
- 141 Corp., Armonk, NY).

143 **3. Results**

Table 1 shows the baseline characteristics of the subjects according to SMI group.
The subjects with Class I sarcopenia had higher weight, waist circumference, fasting
glucose, HOMA-IR, SBP, DBP, triglycerides, and LDL cholesterol compared with
normal SMI subjects. In contrast, the subjects with Class I sarcopenia had lower SMI,
ALM/BMI, and leg power compared with normal SMI subjects.

149 Kaplan-Meier curves for events of incident MetS according to baseline SMI. Fig 1 150 shows the Kaplan-Meier curves for events of incident MetS according to baseline SMI, 151 and the subjects with Class I sarcopenia defined by SMI had significantly higher incident 152 of MetS during follow-up period (P = 0.018). Fig. 2 shows the subjects with Class I 153 sarcopenia defined by ALM/BMI had also significantly higher incident of MetS (P <154 0.001). In contrast, high ALM/height² or high absolute ALM had significantly higher 155 incident of MetS (P < 0.001). Fig. 3 shows the Kaplan-Meier curves for events of incident 156 MetS according to baseline leg power, and the subjects with low leg power had 157 significantly higher incident of MetS (P = 0.032).

158 Cox proportional hazard regression analyses were performed in Table 2. We found 159 that the subjects with Class I sarcopenia defined by SMI or ALM/BMI was significantly 160 associated with an increased adjusted hazard ratio (AHR) for incident MetS (3.22, 95%CI 161 1.25-8.27 for SMI, and 3.19, 95%CI 1.31-7.74 for ALM/BMI) compared with the 162 subjects with normal relative skeletal muscle mass, after adjusting age, family history of 163 diabetes, smoking status, and physical activity. In contrast, for the leg power per body 164 weight, the incidence of MetS was not significantly different between low leg power and 165 normal leg power groups after adjusting those variables (AHR = 1.23, 95%CI; 0.50-3.04).

166

167 **4. Discussion**

The major findings of this 7-year prospective study was subjects with Class I sarcopenia defined by SMI (ALM/weight × 100%) or ALM/BMI was significantly associated with an increased adjusted HR for incident MetS compared with the subjects with normal skeletal muscle mass, after adjusting age, family history of diabetes, smoking status, and physical activity. In contrast, the incidence of MetS was not significantly different between low leg power and normal leg power groups after adjusting those variables.

175 Skeletal muscle mass (SMM) is strongly correlated with body size [20]. Thus, 176 EWGSOP2 stated that "when quantifying muscle mass, the absolute level of SMM or 177 ALM can be adjusted for body size in different ways, namely using height squared 178 (ALM/height²), weight (ALM/weight) or body mass index (ALM/BMI) [2]." Preferred 179 adjustment has been a subject of debate. Janssen et al. indicated that SMM/weight is 180 associated with functional impairment and disability in NHANES III participants aged 18 181 and older [21]. Janssen also indicated that SMM/height² is associated with physical 182 disability in the subjects aged 65 and older in Cardiovascular Health Study (CHS) 183 database [22]. Furushima et al. indicated low ALM/height² is associated with bone 184 mineral density but not with MetS variables, and ALM/weight is associated with MetS 185 variables but not with bone mineral density [13]. Many previous studies also indicated 186 that ALM/weight is associated with MetS [9-13]. A recent study found the significant 187 association between low ALM/weight and MetS development in a 7-year retrospective

188 study [23]. The result of the current study is consistent with those cross-sectional studies 189 or the retrospective study, and this is the first prospective study to examine the association 190 of low ALM/weight or ALM/BMI and MetS development, to the best of our knowledge. 191 On the contrary, high ALM/height² or high absolute ALM had significantly higher 192 incident of MetS during the follow-up period. This is consistent with the recent cross-193 sectional study [24] and previous studies [7-14]. It is because the people who have higher 194 body weight tend have higher muscle mass. Therefore, the normalization of muscle mass 195 by body weight or BMI is needed to examine the association between SMM and MetS.

196 The association between muscle strength or power and MetS has also been 197 examined. Jurca et al. indicated that low muscular strength index computed by combining 198 the one-repetition maximum score for the bench press and the leg press expressed as 199 weight lifted per kilogram body weight was significantly associated with high prevalence 200 of MetS [7, 8]. Very recently, Zhang et al. examined the association between the 201 prevalence of MetS and absolute or relative values of muscle strength in women [14]. 202 They concluded that the prevalence of MetS increased with low relative grip and leg 203 strengths (per kilogram body weight). Conversely, low absolute muscle strength was 204 associated with low MetS prevalence [14]. The current longitudinal study showed the 205 significant association between low relative muscle power and the development of MetS, 206 but the association was no more significant after adjusting age, family history of diabetes, 207 smoking status, and physical activity.

208 Several mechanisms may affect the association between low relative skeletal 209 muscle mass and development of MetS, including physical inactivity, malnutrition, 210 insulin resistance, inflammation, and myokines [11]. Skeletal muscle is the main site of

211 glucose uptake and utilization. Low relative skeletal muscle mass may increase insulin 212 resistance and thereby induce MetS. Actually, the HOMA-IR was negatively associated 213 with low relative muscle mass.

214 This study has several limitations. First, because of limited sample size, we could 215 not test many adjusting variables in this study. There may be possible cofounders between 216 low relative skeletal muscle mass and development of MetS. Second, the muscle quality 217 and composition, such as fat infiltration [25, 26], fibrosis [27, 28], relative expansion of 218 extracellular compartments [3, 29, 30], are important issue to assess muscle tissues. 219 However, we could only assess ASM in this study. Further studies are needed to address 220 this issue. Third, recently, BIA is used many studies to assess ASM, but the BIA method 221 is a secondary indirect method to estimate body composition [31]. BIA is possibly 222 influenced by edema, exercise, circadian and seasonal variations [32-34]. Although BIA 223 was measured in the morning without any exercise and fasting state in this study, still 224 seasonal variations may affect the current results.

225

226 **5.** Conclusions

In conclusion, our results show the relative skeletal muscle mass against body weight (ALM/weight) or body mass index (ALM/BMI) is negatively associated the future development of MetS. The relative skeletal muscle mass was negatively associated with HOMA-IR. To maintain the relative skeletal muscle mass is important to prevent developing MetS in Japanese women.

233 Funding: The study was funded by the Ministry of Health, Labour and Welfare (Health 234 and Labour Sciences Research Grant: 200825016B and 201222028B).

235

236 Acknowledgments: The authors thank Dr. Kumpei Tanisawa, Dr. Harumi Ohno, Dr. 237 Kana Konishi, Dr. Michiya Tanimoto, Dr. Noriko Tanaka, Dr. Hiroshi Kawano, Dr. 238 Kenta Yamamoto, Dr. Motoyuki Iemitsu, Ms. Azusa Sasaki, Ms. Yumi Ohmori, Ms. Rie 239 Katayama, Mr. Zhenbo Cao, Ms. Eriko Kubo, Ms. Miyuki Hayashi, Mr. Satoshi Hanawa, 240 Ms. Naeko Kurose, Ms. Aiko Hirosako, Ms. Sayaka Nakamura, Ms. Hidemi Hara, Ms. 241 Miki Yoshida, Mr. Satoshi Kurita, Ms. Noriko Wada, Ms. Miho Okamoto, Ms. Hisako 242 Ito, Ms. Kinue Nakajima, Ms. Kaori Sato, Ms. Akie Morishita, and Ms. Kazumi Kajiwara, 243 who significantly contributed to the realization of this study through their long-term 244 involvement as researchers or research assistants. Moreover, the authors would like to 245 express their gratitude to all the subjects who participated in the study and to all research professionals involved in the NEXIS protocol. 246

247

248 Conflicts of Interest: There is no conflicts of interest in this study.

249

251 **References**

- Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian
 Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis
 and Treatment. J Am Med Dir Assoc. 2020;21(3):300-7.e2. Epub 2020/02/09. doi:
 10.1016/j.jamda.2019.12.012. PubMed PMID: 32033882.
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.
 Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing.
 2019;48(1):16-31. Epub 2018/10/13. doi: 10.1093/ageing/afy169. PubMed PMID:
 30312372; PubMed Central PMCID: PMCPMC6322506.
- Yamada Y, Buehring B, Krueger D, Anderson RM, Schoeller DA, Binkley N.
 Electrical properties assessed by bioelectrical impedance spectroscopy as
 biomarkers of age-related loss of skeletal muscle quantity and quality. The Journals
 of Gerontology Series A: Biological Sciences and Medical Sciences.
 2017;72(9):1180-6. doi: 10.1093/gerona/glw225.
- 265 4. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393(10191):2636-46.
 266 doi: 10.1016/S0140-6736(19)31138-9.
- Usui C, Takahashi E, Gando Y, Sanada K, Oka J, Miyachi M, et al. Resting energy
 expenditure can be assessed by dual-energy X-ray absorptiometry in women
 regardless of age and fitness. Eur J Clin Nutr. 2009;63(4):529-35. Epub 2008/02/21.
 doi: 10.1038/sj.ejcn.1602980. PubMed PMID: 18285810.
- Wang Z, Ying Z, Bosy-Westphal A, Zhang J, Schautz B, Later W, et al. Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. The American journal of clinical nutrition. 2010;92(6):1369-77. Epub 10/20. doi: 10.3945/ajcn.2010.29885.
 PubMed PMID: 20962155.
- Jurca R, Lamonte MJ, Church TS, Earnest CP, Fitzgerald SJ, Barlow CE, et al.
 Associations of muscle strength and fitness with metabolic syndrome in men. Med
 Sci Sports Exerc. 2004;36(8):1301-7. Epub 2004/08/05. doi:
 10.1249/01.mss.0000135780.88930.a9. PubMed PMID: 15292736.
- Jurca R, Lamonte MJ, Barlow CE, Kampert JB, Church TS, Blair SN. Association
 of muscular strength with incidence of metabolic syndrome in men. Med Sci Sports
 Exerc. 2005;37(11):1849-55. Epub 2005/11/16. doi:
 10.1249/01.mss.0000175865.17614.74. PubMed PMID: 16286852.
- 284 9. Kim Y, Han BD, Han K, Shin KE, Lee H, Kim TR, et al. Optimal cutoffs for low
 285 skeletal muscle mass related to cardiovascular risk in adults: The Korea National
 286 Health and Nutrition Examination Survey 2009-2010. Endocrine. 2015;50(2):424-

287 33. Epub 2015/04/12. doi: 10.1007/s12020-015-0577-y. PubMed PMID:
288 25862070.

- Mesinovic J, McMillan LB, Shore-Lorenti C, De Courten B, Ebeling PR, Scott D.
 Metabolic Syndrome and Its Associations with Components of Sarcopenia in
 Overweight and Obese Older Adults. Journal of clinical medicine. 2019;8(2). Epub
 2019/01/30. doi: 10.3390/jcm8020145. PubMed PMID: 30691198; PubMed
 Central PMCID: PMCPMC6406767.
- Kim SH, Jeong JB, Kang J, Ahn DW, Kim JW, Kim BG, et al. Association between
 sarcopenia level and metabolic syndrome. PloS one. 2021;16(3):e0248856. Epub
 2021/03/20. doi: 10.1371/journal.pone.0248856. PubMed PMID: 33739984;
 PubMed Central PMCID: PMCPMC7978348 salaries. This does not alter our
 adherence to all PLOS ONE policies on sharing data and materials.
- 299 Kim BC, Kim MK, Han K, Lee SY, Lee SH, Ko SH, et al. Low muscle mass is 12. 300 associated with metabolic syndrome only in nonobese young adults: the Korea 301 National Health and Nutrition Examination Survey 2008-2010. Nutrition research 302 (New York. NY). 2015;35(12):1070-8. Epub 2015/11/26. doi: 303 10.1016/j.nutres.2015.09.020. PubMed PMID: 26602833.
- Furushima T, Miyachi M, Iemitsu M, Murakami H, Kawano H, Gando Y, et al.
 Comparison between clinical significance of height-adjusted and weight-adjusted
 appendicular skeletal muscle mass. J Physiol Anthropol. 2017;36(1):15. Epub
 2017/02/15. doi: 10.1186/s40101-017-0130-1. PubMed PMID: 28193296; PubMed
 Central PMCID: PMCPMC5307800.
- 309 14. Zhang W, Zhao Z, Sun X, Tian X. Prevalence of Metabolic Syndrome According
 310 to Absolute and Relative Values of Muscle Strength in Middle-Aged and Elderly
 311 Women. International journal of environmental research and public health.
 312 2021;18(17). Epub 2021/09/11. doi: 10.3390/ijerph18179073. PubMed PMID:
 313 34501662; PubMed Central PMCID: PMCPMC8431152.
- Fuku N, Murakami H, Iemitsu M, Sanada K, Tanaka M, Miyachi M. Mitochondrial
 macrohaplogroup associated with muscle power in healthy adults. Int J Sports Med.
 2012;33(5):410-4. Epub 2012/03/02. doi: 10.1055/s-0031-1301317. PubMed
 PMID: 22377945.
- Yamada Y, Hashii-Arishima Y, Yokoyama K, Itoi A, Adachi T, Kimura M.
 Validity of a triaxial accelerometer and simplified physical activity record in older
 adults aged 64-96 years: a doubly labeled water study. Eur J Appl Physiol. 2018.
 Epub 2018/07/19. doi: 10.1007/s00421-018-3944-6. PubMed PMID: 30019086.

322 Yamada Y, Yokoyama K, Noriyasu R, Osaki T, Adachi T, Itoi A, et al. Light-17. 323 intensity activities are important for estimating physical activity energy expenditure 324 using uniaxial and triaxial accelerometers. Eur J Appl Physiol. 2009;105(1):141-52 325 Erratum in: 16(6):1279. doi: DOI 10.1007/s00421-008-0883-7.

- 326 18. Gando Y, Yamamoto K, Murakami H, Ohmori Y, Kawakami R, Sanada K, et al. 327 Longer time spent in light physical activity is associated with reduced arterial 328 stiffness in older adults. Hypertension. 2010;56(3):540-6. Epub 2010/07/08. doi: 329 10.1161/hypertensionaha.110.156331. PubMed PMID: 20606102.
- 330 19. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. 331 Prevalence of metabolic syndrome in the general Japanese population in 2000. 332 Journal of atherosclerosis and thrombosis. 2006;13(4):202-8. Epub 2006/08/16. 333 doi: 10.5551/jat.13.202. PubMed PMID: 16908953.
- 334 Kawakami R, Miyachi M, Tanisawa K, Ito T, Usui C, Midorikawa T, et al. 20. 335 Development and validation of a simple anthropometric equation to predict 336 appendicular skeletal muscle mass. Clinical Nutrition. 2021;40(11):5523-30. doi: 337 10.1016/j.clnu.2021.09.032.
- 338 Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) 21. 339 in older persons is associated with functional impairment and physical disability. J 340 Am Geriatr Soc. 2002;50(5):889-96. Epub 2002/05/25. doi: 10.1046/j.1532-341 5415.2002.50216.x. PubMed PMID: 12028177.
- 342 22. Janssen I. Influence of sarcopenia on the development of physical disability: the 343 Cardiovascular Health Study. J Am Geriatr Soc. 2006;54(1):56-62. Epub 344 2006/01/20. doi: 10.1111/j.1532-5415.2005.00540.x. PubMed PMID: 16420198.
- 345 Kim G, Lee SE, Jun JE, Lee YB, Ahn J, Bae JC, et al. Increase in relative skeletal 23. 346 muscle mass over time and its inverse association with metabolic syndrome 347 development: a 7-year retrospective cohort study. Cardiovascular diabetology. 348 2018;17(1):23. Epub 2018/02/07. doi: 10.1186/s12933-018-0659-2. PubMed 349 PMID: 29402279; PubMed Central PMCID: PMCPMC5798183.
- 350 Lagacé JC, Marcotte-Chenard A, Paquin J, Tremblay D, Brochu M, Dionne IJ. 24. 351 Increased odds of having the metabolic syndrome with greater fat-free mass: 352 counterintuitive results from the National Health and Nutrition Examination Survey 353 database. J Cachexia Sarcopenia Muscle. 2021. Epub 2021/11/27. doi: 354 10.1002/jcsm.12856. PubMed PMID: 34825787.
- 355 Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation 25. 356 determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000;89(1):104-10. 357

358 26. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, et
al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC
360 Study. J Appl Physiol. 2001;90(6):2157-65.

- 361 27. Fukumoto Y, Ikezoe T, Yamada Y, Tsukagoshi R, Nakamura M, Mori N, et al.
 362 Skeletal muscle quality assessed from echo intensity is associated with muscle
 363 strength of middle-aged and elderly persons. Eur J Appl Physiol.
 364 2012;112(4):1519-25. Epub 2011/08/19. doi: 10.1007/s00421-011-2099-5 [doi].
 365 PubMed PMID: 21847576.
- Watanabe Y, Yamada Y, Fukumoto Y, Ishihara T, Yokoyama K, Yoshida T, et al.
 Echo intensity obtained from ultrasonography images reflecting muscle strength in
 elderly men. Clin Interv Aging. 2013;8:993-8. Epub 2013/08/09. doi:
 10.2147/CIA.S47263
- Yamada Y, Yoshida T, Yokoyama K, Watanabe Y, Miyake M, Yamagata E, et al.
 The Extracellular to Intracellular Water Ratio in Upper Legs is Negatively
 Associated With Skeletal Muscle Strength and Gait Speed in Older People. The
 Journals of Gerontology: Series A. 2017;72(3):293-8. doi: 10.1093/gerona/glw125.
- 374 Yamada Y, Schoeller DA, Nakamura E, Morimoto T, Kimura M, Oda S. 30. 375 Extracellular water may mask actual muscle atrophy during aging. The Journals of 376 Gerontology Series A: **Biological** Sciences and Medical Sciences. 377 2010;65A(5):510-6.
- 378 31. Yamada Y, Nishizawa M, Uchiyama T, Kasahara Y, Shindo M, Miyachi M, et al.
 379 Developing and Validating an Age-Independent Equation Using Multi-Frequency
 380 Bioelectrical Impedance Analysis for Estimation of Appendicular Skeletal Muscle
 381 Mass and Establishing a Cutoff for Sarcopenia. International journal of
 382 environmental research and public health. 2017;14(7). Epub 2017/07/30. doi:
 383 10.3390/ijerph14070809. PubMed PMID: 28753945; PubMed Central PMCID:
 384 PMCPMC5551247.
- 385 32. Shiose K, Yamada Y, Motonaga K, Sagayama H, Higaki Y, Tanaka H, et al.
 386 Segmental extracellular and intracellular water distribution and muscle glycogen
 after 72-h carbohydrate loading using spectroscopic techniques. J Appl Physiol
 388 (1985). 2016;121(1):205-11. Epub 2016/05/28. doi:
 389 10.1152/japplphysiol.00126.2016. PubMed PMID: 27231310.
- 390 33. Shiose K, Tanabe Y, Ohnishi T, Takahashi H. Effect of regional muscle damage
 and inflammation following eccentric exercise on electrical resistance and the body
 composition assessment using bioimpedance spectroscopy. The journal of

393 physiological sciences : JPS. 2019;69(6):895-901. Epub 2019/08/08. doi:
 394 10.1007/s12576-019-00702-8. PubMed PMID: 31388975.

395 34. Shiose K, Yamada Y, Motonaga K, Takahashi H. Circadian variation of
asegmental bioimpedance of the leg, arm, and trunk in healthy
humans: a segmental bioimpedance spectroscopy study. Biomedical Physics &
Engineering Express. 2017;3(6):065007. doi: 10.1088/2057-1976/aa87c0.

401 Figure legend

402

- 403 Fig. 1 Kaplan-Meier curves for events of incident metabolic syndrome (MetS) according
- 404 to baseline skeletal muscle index (SMI, %). Bold line shows normal SMI, and dashed line
- 405 shows Class I sarcopenia. The SMI was calculated as ALM divided by body weight \times

406 100 (%).

407

408	Fig. 2 Kaplan-Meier curves for events of incident metabolic syndrome (MetS) according
409	to baseline ALM/BMI. Bold line shows normal ALM/BMI, and dashed line shows Class

410 I sarcopenia.

411

412 Fig. 3 Kaplan-Meier curves for events of incident metabolic syndrome (MetS) according
413 to baseline leg power (W/kg). Bold line shows normal leg power, and dashed line shows
414 low leg power.
415

416

Table 1. Baseline characteristics of the study subjects according to SMI group (N =346)										
			Norma	al SMI			С	lass	Ι	
	Above Ave.			Below Ave.			sarcopenia			
SMI (%)	≥32%		28%-32%			<28%			Р	
	n = 81		n = 184			n = 81			value	
	mean	±	SD	mean	±	SD	mean	±	SD	
Age (y)	54.1	±	11.7	56.6	±	11.6	55.7	±	9.3	0.24
Weight (kg)	48.5	±	5.0	53.9	±	5.3	62.0	±	7.4	< 0.001
BMI (kg/m ²)	19.7	±	1.5	21.9	±	2.1	25.2	±	2.8	< 0.001
Waist circumference (cm)	73.3	±	6.2	80.4	±	7.1	90.3	±	7.1	< 0.001
SMI (%)	33.4	±	1.4	30.0	±	1.1	26.5	±	1.1	< 0.001
ALM/BMI	0.825	±	0.079	0.740	±	0.060	0.655	±	0.062	< 0.001
HbA1c (%)	5.4	±	0.5	5.5	±	0.4	5.6	±	0.5	0.115
Fasting glucose (mg/dL)	89.2	±	14.2	89.6	±	11.1	94.0	±	13.0	0.015
HOMA-IR	0.69	±	0.38	0.86	±	0.36	1.39	±	1.16	< 0.001
SBP (mmHg)	114.2	±	18.3	120.0	±	16.8	120.0	±	16.8	0.008
DBP (mmHg)	67.9	±	10.8	71.3	±	10.4	72.1	±	10.1	0.020
HR (bpm)	58.2	±	8.3	59.8	±	9.3	61.3	±	8.7	0.093
Total cholesterol (mg/dL)	210.0	±	37.7	221.1	±	35.4	219.4	±	30.9	0.055
Triglycerides (mg/dL)	70.1	±	31.4	83.0	±	43.1	104.3	±	55.8	< 0.001
HDL cholesterol (mg/dL)	75.5	±	14.7	72.7	±	17.8	62.9	±	11.8	< 0.001
LDL cholesterol (mg/dL)	120.1	±	32.0	131.4	±	30.4	135.3	±	28.3	0.004
PA (METs*hour)	4.4	±	2.9	3.8	±	1.7	3.8	±	1.9	0.077
Leg Power (W/kg)	16.3	±	3.4	14.7	±	4.1	13.8	±	3.8	< 0.001

SMI, skeletal muscle mass index; BMI, body mass index; ALM, appendicular lean mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HDL, high density lipoprotein; LDL, low density lipoprotein; PA, physical activity.

418

Table 2 Association between baseline relative muscle mass or power and incidence of metabolic syndrome (Cox model) (N = 346)

	Model 1	Model 2	Model 3		
	HR (95%CI)	HR (95%CI)	HR (95%CI)		
Normal SMI	1 (ref)	1 (ref)	1 (ref)		
Class I Sarcopenia	2.61 (1.14-5.98)	3.16 (1.35-7.39)	3.22 (1.25-8.27)		
	P = 0.023	P = 0.008	P = 0.015		
Normal ALM/BMI	1 (ref)	1 (ref)	1 (ref)		
Class I Sarcopenia	3.88 (1.74-8.68)	3.52 (1.57-7.92)	3.19 (1.31-7.74)		
	P = 0.001	P = 0.002	P = 0.010		
Normal leg power	1 (ref)	1 (ref)	1 (ref)		
Low leg power	2.34 (1.05-5.22)	1.67 (0.74-3.84)	1.23 (0.50-3.04)		
	P = 0.037	P = 0.214	P = 0.654		

SMI, skeletal muscle mass index; BMI, body mass index; ALM, appendicular lean mass; HR, hazard ratio; CI, confidence interval.

Model 1: crude

Model 2: Model 1 + further adjusted for age

Model 3: Model 2 + further adjusted for family history of diabetes, smoking status, physical activity

420





Fig. 1 422 423



424

425 Fig. 2







